Abstract |
Inhibitor of Apoptosis Proteins (IAPs) are the target of extensive research in the field of cancer therapy since they regulate apoptosis and cell survival. Smac-mimetics, the most promising IAP-targeting compounds specifically recognize the IAP-BIR3 domain and promote apoptosis, competing with caspases for IAP binding. Furthermore, Smac-mimetics interfere with the NF-κB survival pathway, inducing cIAP1 and cIAP2 degradation through an auto-ubiquitination process. It has been shown that the XIAP-BIR1 (X-BIR1) domain is involved in the interaction with TAB1, an upstream adaptor for TAK1 kinase activation, which in turn couples with the NF-κB survival pathway. Preventing X-BIR1 dimerization abolishes XIAP-mediated NF-κB activation, thus implicating a proximity-induced mechanism for TAK1 activation. In this context, in a systematic search for a molecule capable of impairing X-BIR1/TAB1 assembly, we identified the compound NF023. Here we report the crystal structure of the human X-BIR1 domain in the absence and in the presence of NF023, as a starting concept for the design of novel BIR1-specific compounds acting synergistically with existing pro-apoptotic drugs in cancer therapy.
|
Authors | Federica Cossu, Mario Milani, Serena Grassi, Francesca Malvezzi, Alessandro Corti, Martino Bolognesi, Eloise Mastrangelo |
Journal | Proteins
(Proteins)
Vol. 83
Issue 4
Pg. 612-20
(Apr 2015)
ISSN: 1097-0134 [Electronic] United States |
PMID | 25619915
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 Wiley Periodicals, Inc. |
Chemical References |
- Inhibitor of Apoptosis Proteins
- NF-kappa B
- NF023
- Recombinant Proteins
- Suramin
|
Topics |
- Crystallization
- Drug Discovery
- Humans
- Inhibitor of Apoptosis Proteins
(chemistry, metabolism)
- Molecular Docking Simulation
- NF-kappa B
- Protein Structure, Tertiary
- Recombinant Proteins
(chemistry, metabolism)
- Suramin
(analogs & derivatives, chemistry, metabolism)
|